Insmed
INSM
202 hedge funds and large institutions have $3.42B invested in Insmed in 2021 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 89 increasing their positions, 51 reducing their positions, and 24 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 51
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
21% more call options, than puts
Call options by funds: $4.04M | Put options by funds: $3.33M
3.59% more ownership
Funds ownership: 103.46% → 107.05% (+3.6%)
2% more funds holding
Funds holding: 198 → 202 (+4)
6% less capital invested
Capital invested by funds: $3.63B → $3.42B (-$209M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$91.1M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$86.9M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$60.3M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$51.4M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
+$37.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$62.3M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$60.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$48.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$16.5M |
| 5 |
D.E. Shaw & Co
New York
|
-$9.69M |
INSM Hedge Fund Activity: Q2 2021 in Review
202 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q2 2021, worth a combined $3.42B — down 5.8% from $3.63B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new INSM positions and 24 closed out — a net gain of 6 holders — while 89 added to existing stakes and 51 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $91.1M. The largest seller was Lord, Abbett & Co, cutting an estimated $62.3M.
- 202 institutional investors held Insmed (INSM) as of Q2 2021, up from 198 in Q1 2021.
- Funds reported $3.42B of Insmed stock for Q2 2021, down 5.8% quarter-over-quarter.
- 30 funds opened new Insmed positions in Q2 2021 and 24 closed out, a net change of +6 holders.
- The largest Insmed buyer in Q2 2021 was T. Rowe Price Associates, an estimated $91.1M added.
- The largest Insmed seller in Q2 2021 was Lord, Abbett & Co, an estimated $62.3M sold.
Based on aggregated 13F filings for Q2 2021.